LETTER TO JMG

Interleukin-1 cluster is associated with genetic risk for schizophrenia and bipolar disorder

S Papiol, A Rosa, B Gutierrez, B Martin, P Salgado, R Catalan, B Arias, L Fañanás

Key points

- Several studies have suggested that schizophrenia and bipolar disorder are on a continuum of liability. Both disorders share psychopathological dimensions, psychiatric symptoms, and risk factors. Furthermore, family and linkage studies lend credence to the presence of a common genetic risk background.
- Altered levels of cytokines have been found in these mental disorders. Genes coding for interleukin-1β (IL-1β) and interleukin-1 receptor antagonist (IL-1Ra) are possible candidate genes due to the role of these cytokines in neurodevelopment and neurodegeneration, processes which might be involved in the origin of psychosis.
- We analysed a polymorphism in the promoter region (−511) of the IL-1β gene and an 86 bp VNTR in intron 2 of the IL-1Ra gene in schizophrenic and bipolar patients and in healthy controls.
- A significant excess of the haplotypic combination −511 allele*1/VNTR allele*2 was found both in schizophrenic (P = 0.0015; OR = 2.49 [95% confidence interval (CI): 1.33 to 4.64]) and bipolar patients (P = 0.004; OR = 2.26 [95% CI: 1.22 to 4.17]) when compared with controls. The highest risk conferred by this risk haplotype was detected in bipolar patients with a family history of schizophrenia, bipolar disorder, or severe major depression (P = 0.00009; OR = 3.18 [95% CI: 1.66 to 6.05]).
- IL-1 cluster genetic variability may represent a shared genetic susceptibility factor both for schizophrenia and bipolar disorder.

S chizophrenia and affective psychoses are severe and prevalent psychiatric disorders described in all cultures and populations. Whether these functional psychoses are two distinct disorders, or are closely related in aetiology, has been debated in the literature during the last century.1–4 Several studies have suggested that schizophrenia and bipolar disorder are on a continuum of liability. Psychopathological dimensions and psychiatric symptoms shared by both groups of patients would be compatible with this overlap.5 Likewise, other risk factors, such as cerebral ventricle enlargement,6 markers of prenatal suffering,7 or life events,8 have been described in both mental disorders. Recent molecular linkage studies have suggested the possible existence of shared disease loci for both disorders.9 Of special interest are the family studies showing that first degree relatives of bipolar patients have a three times increased risk for schizophrenia compared with first degree relatives of controls.10 11 These data suggest the presence of a common genetic risk background in both disorders. However, it should be noted that other family studies have not been able to replicate these latter results.12 13

Over the last decade, several studies have reported an imbalance in pro-inflammatory/anti-inflammatory cytokines or their soluble receptors level in plasma or cerebrospinal fluid of schizophrenic and bipolar disorder patients.14 15 These results have been replicated by recent studies in both diagnostic groups.16 17

Genes coding for some of these cytokines are located on the IL-1 cluster within chromosome 2q13. This cluster contains nine genes of the IL-1 family of cytokines (IL-1A, IL-1B, IL-1RN, and IL-1F5–F10).18 Several polymorphic variants of these genes have been associated with human diseases.19

The IL-1β gene (IL-1B) consists of seven exons with an extension of 7 kb and codes for a precursor form (proIL-1β) which is cleaved by a protease (ICE) to give the active IL-1β form. This pro-inflammatory cytokine is involved in acute and chronic neurodegeneration20 and in embryonic development of the CNS.21 During CNS neurodevelopment, IL-1β promotes proliferation and production of cytokines and trophic factors, such as nerve growth factor (NGF), in astrocytes22 and inhibits normal expression of brain-derived neurotrophic factor (BDNF).23 In addition, IL-1 (α and β) participates in differentiation of mesencephalic progenitor cells into dopaminergic neurons in cell culture.24

On the other hand, the IL-1Ra gene (IL-1RN) consists of seven exons in a region of 16 kb, and several splice variants can be obtained from the coding sequence. Its product, IL-1 receptor antagonist (IL-1Ra), is an endogenous antagonist at IL-1 receptors and modulates the action of IL-1 agonists. Altered levels of IL-1Ra have been described in the pathogenesis of several diseases where inflammatory or autoimmune processes are involved.25

Recent studies have shown that drug-naïve schizophrenic patients exhibit a significant increase in both IL-1β and IL-1Ra plasma levels when compared with healthy controls.14 16 26; it is generally agreed that regulatory processes affecting IL-1 function are, at least in part, determined by genetic variation.27 Thus, production of IL-1β and IL-1Ra may be modulated by the effect of polymorphisms in the IL-1 cluster.

Unfortunately, data regarding the functional effect of these polymorphisms on cytokine production are unclear and even contradictory. Taken together, all functional data suggest that allelic status in both IL-1B and IL-1RN genes determines, acting coordinately, the levels of these proteins.27–29

Over the last few years, genetic studies have shown an association of polymorphisms in the IL-1 cluster with either schizophrenia or clinical subgroups of this disorder.26 30 31

Abbreviations: BP, bipolar disorder; CI, confidence intervals; FH, family history; OR, odds ratio
The aim of the present study was to investigate the role of certain polymorphic variants of genes of the IL-1 gene cluster in susceptibility to functional psychosis. For this purpose we analysed a SNP at the promoter region (−511C/T; rs16944) of the IL-1B gene and a pentanucleotide 86 bp tandem repeat in intron 2 of the IL-1RN gene in a sample of 78 schizophrenic patients, 88 bipolar disorder patients, and 176 healthy controls.

MATERIALS AND METHODS

Subjects

The schizophrenic patients’ sample consisted of 78 unrelated DSM-IV diagnosed patients (mean age: 31.1 years, SD 7.5) from two public mental health centres in Barcelona: the Mental Health Service of the Eixample district (n = 38) and the Institut Municipal d’Urgeccies Psiquiatriques (IMPU) (n = 40). Diagnoses were determined by experienced psychiatrists using the Spanish version of the Structural Clinical Interview for DSM-IV (SCID-I). The mean evolution time in patients since the first episode was 15.9 years (SD 12.9) and the mean age at onset was 29.5 years (SD 12.9). Diagnoses were determined by experienced psychiatrists using the Spanish version of the Structural Clinical Interview for DSM-IV (SCID-I). The mean evolution time in patients since the first episode was 15.9 years (SD 12.9) and the mean age at onset was 29.5 years (SD 12.9). Information about any family psychiatric history of schizophrenia, bipolar disorder (BP), or severe major depression was determined in bipolar patients using the Spanish version of the structured interview Family History-Research Diagnostic Criteria (FH-RDC).12 This information was obtained by experienced psychiatrists from personal interviews with at least two healthy first degree relatives of each patient. According to this interview, 67% of the sample showed a positive family history of severe mental disorder (schizophrenia, bipolar disorder, and/or severe major depression) in at least a first degree relative. This sample consisted of a group of inpatients presenting an extremely severe outcome (see Vallécs et al11 for additional details about the clinical profile of this sample and its psychiatric familial morbidity risk).

The control group consisted of 176 healthy individuals (mean age: 39.82 years, SD 10.35) recruited from the catchment area of the hospitals involved in this study and can be considered to be representative of the general population of Barcelona. These subjects were interviewed in order to verify that there was no personal history of severe mental illness. Additionally, the Spanish version of the 28-item General Health Questionnaire (GHQ)13 was used to assess current mental condition. All controls and patients showing a positive personal history of neurological disease, cancer, diabetes, or drug or alcohol abuse were excluded from the study.

All cases and controls were of white Spanish origin, shared similar sociodemographic profiles and were comparable as regards the geographical origin of their families.

All subjects gave written informed consent for the study prior to inclusion. The study protocol was approved by the ethical committees of each centre.

Molecular analysis

Genomic DNA was extracted from blood samples using standard phenol-chloroform methods. The −511 AvaI polymorphic site located on the promoter region of the IL-1B gene and the 86 bp repeat of the IL-1Ra gene were genotyped as described previously by Katila et al.25 Allele 1 (−511 C) of the IL-1B gene completes an AvaI restriction site giving products of 190+114 bp after enzymatic digestion, while allele 2 (−511 T) gives an intact product of 304 bp. When the 86 bp repeat in intron 2 of the IL-1Ra gene was analysed, five alleles (A1–A5) were detected in accordance with the number of repeats (2–6).

Statistical analysis

The presence of Hardy–Weinberg equilibrium for genotype frequencies was defined in the samples of patients and controls using χ² tests. Simple χ² tests of independence were also performed to confirm the presence or absence of allele or genotype associations. Odds ratios (OR) with 95% confidence intervals (CI) were estimated for the effects of high-risk genotypes and alleles.

The ARLEQUIN program was used to estimate the haplotypes and their frequencies according to genotype information (expectation maximisation (EM) algorithm) as well as to determine the statistical significance of linkage disequilibrium.34

RESULTS

Frequencies observed for genotypes and alleles in control, bipolar, and schizophrenic samples are shown in tables 1 and 2. Given the allelic frequencies obtained in the general population for the −511 C/T polymorphism, our sample had 80% power (95% CI) to detect an allelic association that confers a risk greater than or equal to 2.50 (in schizophrenic patients) or 2.39 (in bipolar patients). In the case of 86 bp VNTR, our sample had 80% power (95% CI) to detect an allelic association that confers a risk greater than or equal to 2.33 (schizophrenia) or 2.25 (bipolar disorder). All groups showed Hardy–Weinberg equilibrium for the analysed genetic variability (data not shown). No differences were observed when allele, genotype, and haplotype frequencies were compared between females and males in both patient and control groups (data not shown).

An excess of allele 1 (−511C) close to statistical significance was detected when allelic frequencies of the −511 C/T polymorphism were analysed in schizophrenic patients compared to controls (allele: χ² = 3.79, P = 0.051; OR = 1.50 (95% CI: 0.98 to 2.31)) (table 1). No statistical differences with controls were found for allelic or genotypic frequencies distribution in the bipolar disorder sample.

For analysis of the IL-1Ra gene 86 bp repeat, alleles A3, A4, and A5 were considered as a single allele due to their low frequencies. Likewise, genotypes containing these infrequent alleles were also considered as a single genotype (table 2). Allelic and genotypic frequencies of schizophrenic and bipolar patients did not differ from those found in controls.

There is evidence supporting the existence of strong linkage disequilibrium between IL-1 cluster loci.15 36 Given the genotypic frequencies in our samples, a haplotypic analysis was conducted in order to estimate haplotypic frequencies (table 3). Linkage between this pair of loci was found to be significant in both the control (P<0.00001) and bipolar (P = 0.01) samples, but not in the schizophrenic sample.

In order to be consistent with previous studies, haplotypes containing A3, A4, or A5 alleles of the IL-1RN polymorphism were considered as a single haplotypic combination due to their low frequencies. The estimated haplotypic frequencies in our Spanish control sample were similar to those described in previous studies in North American white, Scottish, and Polish populations.17 38

Statistically significant differences were found when we compared the haplotype distribution of cases and controls (schizophrenia: χ² = 12.70, P = 0.012; bipolar disorder: χ² = 9.81, P = 0.043). It should be noted that the haplotypic combination −511 (allele 1)-VNTR (allele 2) was increased
from two to three times in patients compared to controls. Thus, for the next comparisons we considered all possible haplotypic combinations as a single group except for the −511 (allele 1)-VNTR (allele 2) combination in order to estimate the risk conferred by this haplotype. When odds ratios were calculated, this haplotypic combination was found to confer a significantly increased risk both for schizophrenia ($\chi^2 = 9.99, P = 0.0016; OR = 2.49 \ (95\% \ CI: 1.33 \text{ to} 4.64))$ and bipolar disorder ($\chi^2 = 8.09, P = 0.004; OR = 2.26 \ (95\% \ CI: 1.22 \text{ to} 4.17))$. When only individuals of the bipolar sample with a positive family history of schizophrenia, bipolar disorder, or severe major depression in at least a first degree relative were considered, the effect of this haplotype became even more important ($\chi^2 = 15.41, P = 0.00009; OR = 3.18 \ (95\% \ CI: 1.66 \text{ to} 6.05))$.

**DISCUSSION**

To our knowledge, this is first time that IL-1 related polymorphisms have been analysed in a sample of bipolar patients. Previous studies have suggested that these polymorphisms of the **IL-1β** and **IL-1RN** genes may influence susceptibility to schizophrenia. Katila et al. reported a positive association with schizophrenia for the combination −511 (allele 1)-VNTR (allele 1), as opposed to −511 (allele 1)-VNTR (allele 2) in the present study. Meisenzahl et al. and Rosa et al. described an association of −511 (allele 2) with schizophrenia and, more specifically, with clinical subgroups of this disorder. Meisenzahl and colleagues described an excess of allele 2 in schizophrenic patients showing decreases in bfrontal-temporal gray matter volume and generalised white matter tissue deficits. Rosa and colleagues found the same allele 2 associated with depressive dimension in schizophrenia. In addition, other genetic studies have reported a negative association between the **IL-1β** gene and schizophrenia. It should be noted that none of these studies used the haplotypic approach presented in the current report: owing to the strong linkage disequilibrium between loci located on the IL-1 cluster, analysis of haplotypes would be the most appropriate method to study the involvement of this genomic region in psychiatric disorders.

Our findings on the strongest effect size observed in the bipolar patients with a positive family history should be interpreted carefully. As mentioned above, this sample presents an extremely severe outcome. These patients were selected for severity and chronicity of illness course and displayed high rates of psychotic symptoms and high rates of schizophrenia in their first degree relatives. All these data suggest that the positive family history subgroup would include those patients with a higher genetic loading, which would allow us to detect the increased effect found in these patients. In this sense it is interesting to note that recent findings implicating **neuregulin 1** gene as a schizophrenia susceptibility locus also reported that a risk haplotype was enriched in those schizophrenic patients showing a positive family history of schizophrenia.

Cytokine production seems, at least in part, to be genetically determined, but the exact functional role of these polymorphisms of the **IL-1B** and **IL-1RN** genes remains

### Table 1

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>Genotype frequency (%)</th>
<th>Allele frequency (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1.1</td>
<td>1.2</td>
</tr>
<tr>
<td>Schizophrenia</td>
<td>78</td>
<td>39</td>
</tr>
<tr>
<td>Bipolar disorder [BP]</td>
<td>88</td>
<td>38</td>
</tr>
<tr>
<td>BP FH+</td>
<td>59</td>
<td>27</td>
</tr>
<tr>
<td>Controls</td>
<td>176</td>
<td>69</td>
</tr>
</tbody>
</table>

FH+: patients with at least a first degree relative suffering from schizophrenia, bipolar disorder, or severe major depression.

### Table 2

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>Genotype frequency (%)</th>
<th>Allele frequency (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>A1/A1</td>
<td>A1/A2</td>
</tr>
<tr>
<td>Schizophrenia</td>
<td>78</td>
<td>35</td>
</tr>
<tr>
<td>Bipolar disorder [BP]</td>
<td>88</td>
<td>36</td>
</tr>
<tr>
<td>BP FH+</td>
<td>59</td>
<td>22</td>
</tr>
<tr>
<td>Controls</td>
<td>175</td>
<td>91</td>
</tr>
</tbody>
</table>

FH+: patients with, at least, a first degree relative suffering from schizophrenia, bipolar disorder, or severe major depression.

For all comparisons, A3, A4, and A5 were considered a single allele, and genotypes containing the A3, A4, or A5 allele were considered a single genotype.

Schizophrenia v controls: allele: $\chi^2 = 0.33, P = 0.84$; genotype: $\chi^2 = 1.62, P = 0.65$.

Bipolar disorder v controls: allele: $\chi^2 = 3.81, P = 0.15$; genotype: $\chi^2 = 3.63, P = 0.30$.

Bipolar disorder FH+ v controls: allele: $\chi^2 = 4.50, P = 0.105$; genotype: $\chi^2 = 4.08, P = 0.253$. 
unclear. Although it has been comprehensively reported that IL-1β exerts a pro-inflammatory function and IL-1Ra plays an anti-inflammatory role in the immune response, the underlying mechanisms by which these cytokines act are not yet fully understood. We hypothesise that an imbalance in the ratio between pro-inflammatory and anti-inflammatory cytokines may affect embryonic neurodevelopment and promote neurodegeneration in adulthood.20,21 Additionally, IL-1β plays a key role in the dopaminergic differentiation of neural progenitors.22 It should be mentioned that alterations in the dopaminergic system have been classically related to the origin of functional psychoses and, particularly, to the origin of positive symptoms. According to evidence mentioned above, the polymorphic regions analysed in this study, which are thought to confer subtle changes in the expression pattern of the IL-1β and IL-1RN genes, could contribute, with a moderate effect, to destabilising the pro-inflammatory/anti-inflammatory equilibrium during neurodevelopment.

On the other hand, we cannot exclude the possibility that other genetic variants may exist near or within the IL-1 cluster in linkage disequilibrium with the genetic variability analysed in this study and be directly involved in the origin of both mental disorders.

Some methodological limitations should be taken into account when interpreting our results. Although the subjects were of white Spanish origin and from the same community, we cannot rule out the possibility of a population structure account when interpreting our results. Although the subjects analysed in this study and be directly involved in the origin of other genetic variants may exist near or within the IL-1 cluster, are needed in order to confirm or reject these results.

In conclusion, our data suggest that genetic variability in the IL-1 cluster may contribute to a shared genetic risk background of vulnerability for both schizophrenia and bipolar disorder.

ACKNOWLEDGEMENTS
Sergi Papiol was supported by a grant from the Ministry of Education and Culture of Spain (MECD). The authors would like to thank Vicenc Vallés, Roser Guillamat, and Rafael Penadés for their participation in the collection of bipolar and schizophrenic samples. We would like to thank the participating patients and their families, whose generous contributions have made this study possible.

Table 3 Estimated haplotype frequencies of the −511C/T/intron 2 VNTR polymorphisms in patients with schizophrenia, patients with bipolar disorder (BP) with a positive family history (FH+), and the control group.

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>n</th>
<th>−511C−/TNTR(A1)</th>
<th>−511C+/TNTR(A2)</th>
<th>−511T−/TNTR(A1)</th>
<th>−511T+/TNTR(A2)</th>
<th>Others</th>
</tr>
</thead>
<tbody>
<tr>
<td>Schizophrenia</td>
<td>78</td>
<td>81 (51.8%)</td>
<td>17 (10.8%)</td>
<td>27 (17.4%)</td>
<td>26 (16.7%)</td>
<td>5 (3.3%)</td>
</tr>
<tr>
<td>Bipolar disorder (BP)</td>
<td>88</td>
<td>85 (48.1%)</td>
<td>30 (16.8%)</td>
<td>26 (15.0%)</td>
<td>27 (15.5%)</td>
<td>8 (4.6%)</td>
</tr>
<tr>
<td>BP FH+</td>
<td>59</td>
<td>52 (44.1%)</td>
<td>17 (14.5%)</td>
<td>20 (16.9%)</td>
<td>24 (20.3%)</td>
<td>5 (4.2%)</td>
</tr>
<tr>
<td>Controls</td>
<td>173</td>
<td>179 (51.3%)</td>
<td>62 (17.8%)</td>
<td>71 (20.2%)</td>
<td>26 (7.3%)</td>
<td>12 (3.4%)</td>
</tr>
</tbody>
</table>

FH+: patients with, at least, a first degree relative suffering from schizophrenia, bipolar disorder, or severe major depression. For all comparisons, the haplotypes containing A3, A4, or A5 alleles of the IL-1RN VNTR were considered as a single haplotypic combination.

For comparisons, the haplotype distributions: $\chi^2 = 12.70$, P = 0.012. Bipolar disorder vs. controls: haplotype distribution: $\chi^2 = 9.81$, P = 0.043. Bipolar disorder FH+ vs. controls: haplotype distribution: $\chi^2 = 15.90$, P = 0.0031. Schizophrenia vs. controls: haplotype (−511C−/TNTR (A2)) vs other haplotypes: $\chi^2 = 9.99$, P = 0.0015; OR = 2.49 (95% CI: 1.33 to 4.64). Bipolar disorder vs. controls: haplotype (−511C−/TNTR (A2)) vs other haplotypes: $\chi^2 = 8.09$, P = 0.004; OR = 2.26 (95% CI: 1.22 to 4.17). Bipolar disorder FH+ vs. controls: haplotype (−511C−/TNTR (A2)) vs other haplotypes: $\chi^2 = 15.41$, P = 0.00009; OR = 3.18 (95% CI: 1.66 to 6.05).

REFERENCES
10 Sham PC, Jones P, Russell A, Gilvarry K, Bebbington P, Lewis S, Toone B, Murray R. Age at onset, sex, and familial psychiatric morbidity in Table 3 Estimated haplotype frequencies of the −511C/T/intron 2 VNTR polymorphisms in patients with schizophrenia, patients with bipolar disorder (BP) with a positive family history (FH+), and the control group.


25. Akiyama K. Serum levels of soluble IL-2 receptor alpha, IL-6 and IL-1 receptor antagonist in schizophrenia before and during neuroleptic administration. Schizophr Res 1999;37:97–106.


27. Hurme M, Santtila S. IL-1 receptor antagonist (IL-1Ra) plasma levels are coordinately regulated by both IL-1Ra and IL-1beta genes. Eur J Immunol 1998;28:2598–602.


Interleukin-1 cluster is associated with genetic risk for schizophrenia and bipolar disorder

S Papiol, A Rosa, B Gutiérrez, B Martín, P Salgado, R Catalán, B Arias and L Fañanás

doi: 10.1136/jmg.2003.012914

Updated information and services can be found at:
http://jmg.bmj.com/content/41/3/219

These include:

References
This article cites 39 articles, 4 of which you can access for free at:
http://jmg.bmj.com/content/41/3/219#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Psychotic disorders (incl schizophrenia) (29)
- Immunology (including allergy) (603)
- Drugs: endocrine system (106)
- Reproductive medicine (518)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/